Recently, Resmetirom (Rezdiffra, Madrigal Pharmaceuticals, Inc), a thyroid hormone receptor-beta (THRβ) agonist was approved for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis [25]. Here, THRB is linked to Hepatic fibrosis.